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Abstract
Objectives. To examine associations between function, quality of life and structural outcomes in patients achieving
remission vs low disease activity in early RA.
Methods. Demographic, clinical and radiographic variables were collected at baseline and then annually from the Early
Rheumatoid Arthritis Study (ERAS) and Early Rheumatoid Arthritis Network (ERAN) inception cohorts in routine care from
1986 to 2012. Disease activity was categorized: mean DAS28 score between years 1 and 5: remission [mean remission
DAS (mRDAS) <2.6] or low [mean low DAS (mLDAS) 2.63.2]; sustained low/remission DAS28 (sLDAS/sRDAS) at years
1 and 2; and sustained Boolean remission (sBR) at years 1 and 2. Changes in HAQ and Short Form 36 Health Survey
Questionnaire [SF-36; physical (PCS) and mental (MCS) component score]) and total Sharp van der Heijde (SvdH) scores
for each disease activity category were modelled using multi-level models. Covariates included year of onset, age,
gender and DMARD use at first visit.
Results. Of 2701 patients, 562 (21%) were categorized mRDAS, 330 (12%) mLDAS, 279 (10%) sRDAS, 203 (7.5%)
sLDAS and 93 (3%) sBR. Patients categorized as mRDAS had increasingly divergent improved HAQ, SF-36 PCS, MCS
and total SvdH scores compared with mLDAS (P-values 0.001 to <0.0001, all time points). Patients categorized
as sRDAS had better HAQ, SF-36 PCS and MCS scores (P-values 0.05 to <0.0001, all time points) and SvdH scores
(P = 0.05, years 35) over sLDAS. sBR was associated with better HAQ, and SF-36 PCS and MCS scores over sLDAS
(P-values 0.002 to <0.0001, all time points).
Conclusion. These findings from routine care support ACR/EULAR guidelines that remission is a preferable goal over
low disease activity in early RA.
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Rheumatology key messages
. Function, quality of life and structural outcomes are significantly better in remission than low DAS in early RA.
. Differences are more striking using Boolean rather than DAS28 remission criteria.
. These findings support ACR/EULAR guidelines that in early RA the primary goal should be remission.
Introduction
Treat-to-target (T2T) principles are widely recognized as
the best strategy to achieve optimal disease outcomes in
RA [1]. Two target outcomes are proposed within both
ACR and EULAR guidelines [2, 3] and these have been
endorsed by national bodies such as the National Institute
for Health and Care Excellence [4]. These targets are
either remission or low disease activity, with any higher
disease activity state regarded as inadequate disease
control mandating a therapeutic change.
Whilst remission may be the optimal treatment target in
RA, it is hard to achieve and sustain [5]; for example,
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sustained remission was reported in considerably less
than 50% with early RA over 10 years (by various disease
activity criteria) in the Swedish Rheumatology Quality
registry [6]. In contrast, low disease activity, being a less
stringent outcome criterion, is easier to achieve in routine
practice, and tempting for the rheumatologist to adopt as
a T2T goal. Furthermore, in routine practice adherence to
treatment escalation when the target has not been
achieved is low [7, 8], suggesting resistance either from
the patient or health professional. Reasons for this might
include satisfaction with the current overall health and
functional status irrespective of DAS categorization, or
concerns about dose-related treatment adverse effects.
Therefore, an important clinical question is whether
there are important differences in outcomes between RA
patients who achieve remission vs low disease activity.
Comparison of HAQ and radiological damage progression
in two early RA clinical trials in which the T2T strategy was
steered to achieve either DAS remission (RDAS) or low
DAS (LDAS) have shown no differences over 5 years [9].
However, this comparison was of the T2T intention rather
than the actual disease activity achieved. As such, the
actual DAS outcomes achieved in the RDAS and LDAS
steered groups were overlapping at 5 years, with 61%
achieving LDAS in both groups and 43 and 32% achieving
RDAS in each group, respectively.
We have analysed real-life inception cohort early RA
data from the Early Rheumatoid Arthritis Study (ERAS)
and Network (ERAN), with up to 25-year follow-up, explor-
ing differences in outcomes between patient groups who
achieved different DAS categories. Previously we showed
differences in HAQ and structural outcomes between
moderate (3.25.1) and high (>5.1) DAS categories [10].
Here we report functional, Short Form 36 Health Survey
Questionnaire (SF-36) and structural outcomes over
5 years in the ERAS and ERAN cohorts in patients achiev-
ing RDAS using DAS28<2.6 and Boolean remission cri-
teria compared with those achieving LDAS (DAS28
2.63.2).
Methods
Patient databases
The analysis was based on data from two large UK incep-
tion cohorts:
. The ERAS, a multi-centre inception cohort of 1465 pa-
tients with early RA [<2 years disease duration, no
prior conventional synthetic DMARD (csDMARD)].
The recruitment period was 198699, across nine hos-
pitals in England, followed yearly for up to 25 years
(median follow up 10 years).
. The ERAN, a multi-centre inception cohort of 1236
early RA patients (<3 years disease duration). The re-
cruitment period was 200212, across 23 centres in
England, Wales and Ireland, followed yearly for up to
10 years (median follow up 6 years).
Recruitment was based on clinician diagnosis with 70%
of patients fulfilling the minimum ARA criteria for RA [11] at
baseline and 96% by last visit. Patients subsequently
reclassified as non-RA were excluded from the study.
Combined analysis of ERAS and ERAN was possible,
being consecutive inception cohorts with a similar
design and captured variables, as followed in previous
analyses of these cohorts [10, 1214]. Patients with at
least 1 year of follow-up data were included. The ERAS
study received ethical approval from the East
Hertfordshire Local Research Ethics Committee and sub-
sequently the Caldicott Guardian. The ERAN study
received ethical approval from the Trent research ethics
committee.
Clinical, laboratory, functional and other variables
Information on clinical, laboratory, radiographic, functional
features and treatment were recorded in both cohorts at
baseline, between 3 and 6 months, at 12 months and
then once yearly on standardized case report forms [13,
15, 16].
Function and quality of life
HAQ as a measure of function was recorded at every pa-
tient visit. Data on health-related quality of life (QoL) were
only available in ERAN, measured using the SF-36.
Responses were grouped into physical component
score (PCS) and mental component score (MCS). The
PCS includes physical function, pain, physical role func-
tioning and general health, whereas the MCS includes
mental health, vitality, social functioning and social role
functioning. Scores were normed to values from the
general population in England [17] such that a score of
50 is indicative of the average level in the population.
The minimal clinical important difference on an individual
level was taken as 0.22 for HAQ, and 3.0 for SF-36 PCS
and MCS.
Disease activity
Disease activity was calculated according to the original
three-variable method in ERAS (DAS) [18] and the more
recent four-variable DAS28 [19] in ERAN. The original DAS
was converted to DAS28 using a transformation formula
developed by our team, to make the two comparable [20].
Disease activity was categorized by mean score over
years 15 and by sustained scores at years 1 and 2 with
remission defined as DAS28<2.6 and low disease activity
as DAS28 2.63.2. This resulted in the following patient
groups: mean low disease activity years 15 (mLDAS),
mean remission years 15 (mRDAS), sustained low dis-
ease activity years 1 and 2 (sLDAS), sustained remission
years 1 and 2 (sRDAS) and sustained Boolean remission
years 1 and 2 (sBR). Boolean remission was defined as:
swollen joint count, tender joint count, patient global as-
sessment, all 41, and CRP 41 mg/dl. Where a CRP was
not available (60% of all observations), ESR was used at
the level of420 mm/h, guided by the ACR/EULAR criteria
for definition of remission [21, 22]. For categorization into
sLDAS, sRDAS and sBR groups, DAS data had to be
available at both year 1 and 2. For categorization into
mLDAS and mRDAS groups a minimum of one DAS
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data result from years 15 was accepted; however, two or
more DAS scores were available for 86% of patients cate-
gorized as mRDAS and 92% of those categorized as
mLDAS.
Radiographic variables
Plain radiographs of hands and feet undertaken yearly
were used to assess structural joint damage using the
Sharp van der Heijde (SvdH) scoring method. This
included radiographs from all 9 ERAS centres and 7/25
(28%) centres from ERAN, scored by two independent
reviewers, as previously described [23]. The scores were
combined to give a total SvdH score ranging from 0 to
448. The minimal clinical important difference on an indi-
vidual level was taken as 5.0.
Treatment
All centres managed RA according to local practice, influ-
enced by contemporary UK guidelines for management of
RA [24, 25] with treatment choice and strategy at the dis-
cretion of the treating clinician [26]. Median time to first
csDMARD was 2 months after presentation in ERAS and
1 month after presentation in ERAN. Recruiting centres
generally favoured SSZ as first csDMARD choice in
ERAS with a gradual switch to MTX being observed,
such that SSZ and MTX were used in equal proportions
at the start of ERAN (2002) and then MTX became the
most frequent first choice csDMARD thereafter [16]. At
baseline all patients in ERAS were csDMARD naı¨ve and
in ERAN 13.5% had commenced a csDMARD within a few
weeks of first secondary care visit. Combination
csDMARDS were generally used for more severe RA
and were introduced at earlier time points in the later
years of ERAS and in 25% of those who received any
csDMARDs in ERAN [16, 26]. In ERAN the most frequently
used combinations of csDMARDs were MTX/SSZ, MTX/
SSZ + HCQ and MTX/HCQ [26]. Only a small proportion of
patients received biological DMARDs (bDMARDs), which
were available from 2002 onwards (<2% by 1 year and
<10% by 3 years).
Statistical analysis
The primary analysis compared function, QoL and radio-
graphic outcomes between the mRDAS and mLDAS
groups. Secondary analyses compared the same out-
comes between the sRDAS and sLDAS groups, and the
sBR and sLDAS groups. Summary statistics were used to
describe demographic and baseline data between the
groups. HAQ, SF-36 PCS and SF-36 MCS progression
between years 1 and 5 was estimated using linear
mixed effects models, whilst progression of total SvdH
scores between baseline and year 5 was estimated
using negative binomial mixed effects models. Individual
scores at each assessment between baseline and 5 years
were included as outcome variables. All models incorpo-
rated a random intercept and a random slope for time.
This accounts for the repeated observations within-indi-
viduals and allows the level of the outcome at baseline
and the rate of change over time to vary across
individuals. Missing data were inferred by full information
maximum likelihood. Time was modelled using a linear
spline with a change point at 12 months to account for
the non-linear trajectory of all outcomes over time. This
was due to outcomes typically showing an improvement
in the first 12 months, when most initiated treatment,
but then scores plateaued or worsened over the follow-
ing 4 years. DAS28 category was included as dummy-
coded variables with an interaction term with time.
The first model looked at HAQ, SF-36 PCS, SF-36
MCS and SvdH outcomes in mRDAS vs mLDAS,
whereas the second and third models looked at the
same outcomes in sRDAS vs sLDAS and sBR vs
sLDAS groups, respectively. To protect against con-
founding, the analysis controlled for age at RA onset,
gender, calendar year of first visit, use of DMARD treat-
ments at baseline and steroid prescription at baseline.
All analyses were carried out in Stata V.15.1 (StataCorp
LLC, College Station, TX, USA).
Results
Descriptive data
A total of 2701 patients were included in the analysis.
Patients were allocated to the mRDAS and mLDAS
groups on the basis of the mean DAS score over five
annual assessments from years 15, meaning that
scores were not necessarily consistently within the final
allocated DAS group at every annual assessment.
However, the median DAS28 scores of the mRDAS and
mLDAS groups were within the allocated DAS28 categor-
ical range at each annual time point, see Fig. 1. In the
mRDAS group, at each year over 75% of patients had a
DAS28 score in the RDAS range (supplementary Table S1,
available at Rheumatology online) and 97% had more than
half of their annual observations within their allocated
RDAS range. In the mLDAS group there was more vari-
ability, with 2337% of patients having a DAS28 score in
the LDAS range at each year (supplementary Table S2,
available at Rheumatology online), and 34% having more
than half of their five annual observations within the LDAS
range. Reasons for early discontinuation and missing data
are shown in supplementary Table S3, available at
Rheumatology online.
Four patients fulfilled criteria for both sBR and sLDAS,
as the highest permissible scores to satisfy Boolean re-
mission (allowing ESR up to 20 mm/h) produces a DAS28
ESR 3.1 and DAS28 CRP 2.8, both of which are in the
LDAS category. As Boolean remission is the most strin-
gent outcome criterion, it was considered clinically and
statistically appropriate to include these four patients in
the less strict sLDAS group for comparison purposes be-
tween sLDAS and sBR. Sensitivity analysis excluding
these four overlapping patients made no difference to
the overall results.
Table 1 shows the numbers categorized as mRDAS,
mLDAS, sRDAS, sLDAS and sBR, and their baseline
demographic and RA specific covariates. Several baseline
covariates were statistically different between the mRDAS
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and mLDAS groups, including age, gender, ESR, DAS28,
HAQ, SvdH score and SF-36 PCS, with more severe or
worse scores in the patients categorized mLDAS. The
statistically different baseline covariates between the
sRDAS and sLDAS groups were higher proportion
female, ESR and DAS28 in the sLDAS group.
FIG. 1 Box plot of DAS28 scores over years 15 for the mean remission DAS group, and the mean low DAS group
The white line in the middle of the boxes represents the median values, whilst the outer part of the boxes indicates the
25th and 75th percentiles. The whiskers extending from the boxes indicate the upper and lower adjacent values (within
1.5 IQR of the median), whilst the circles outside the whiskers represent outside values. The black dashed lines across
the plots indicate the threshold for remission DAS (2.6) and low DAS (3.2) categorization. IQR: interquartile range.
TABLE 1 Patient demographic and baseline covariates by DAS28 category
mRDAS mLDAS P* sRDAS sLDAS P** sBR
N (%) 562 (21) 330 (12) 279 (10) 203 (7.5) 89 (3)
Age, years [mean (S.D.)] 53.8 (14.35) 56.1 (13.12) 0.014 53.5 (14.23) 55.5 (14.29) 0.135 51.6 (15.87)
Female [n (%)] 288 (51.3) 205 (62.1) 0.002 140 (50.2) 120 (59.11) 0.052 45 (50.6)
RF positive [n (%)]a 303 (57.4) [528] 186 (60.2) [309] 0.426 161 (60.5) [266] 115 (59.6) [193] 0.839 55 (63.2)
BMI [mean (S.D.)]a 26.0 (4.09) [497] 26.3 (4.49) [304] 0.262 25.6 (4.02) [255] 26.0 (4.38) [178] 0.321 25.7 (4.08)
Current smoker [n (%)] 94 (20.6) 67 (26.2) 0.226 39 (17.9) 36 (23.2) 0.348 9 (13.0)
Ex-smoker [n (%)] 132 (28.9) 70 (27.3) 69 (31.7) 41 (26.5) 23 (33.3)
Never smoker [n (%)] 231 (50.6) 119 (46.5) 110 (50.5) 78 (50.3) 37 (53.6)
Missing data [n (%)] 105 (18.7) 74 (22.4) 61 (21.9) 48 (23.6) 20 (21.5)
ESR mmHg/h
[median (IQR)]a
20 (27) [510] 29 (35) [307] <0.001 20 (32) [261] 27.5 (38) [190] 0.015 28.5 (34.5) [84]
Hb g/dl [mean (S.D.)]a 13.2 (1.44) [552] 13.1 (1.41) [326] 0.334 13.2 (1.41) [275] 13 (1.42) [201] 0.241 13 (1.45) [87]
DAS28 [mean (S.D.)]a 4.1 (1.51) [542] 4.4 (1.34) [316] 0.001 4.1 (1.54) [273] 4.4 (1.32) [198] 0.009 4.1 (1.53) [87]
SvdH [median (IQR)]a 6 (14) [302] 7 (19) [195] 0.045 6 (15) [169] 7 (16) [120] 0.171 6 (13) [55]
HAQ [mean (S.D.)]a 0.8 (0.70) [552] 0.9 (0.68) [324] 0.023 0.8 (0.71) [276] 0.9 (0.74) [200] 0.132 0.7 (0.73) [88]
SF-36 MCS [mean (S.D.)]a 51.2 (10.68) [242] 50.2 (11.81) [112] 0.394 52.6 (10.07) [90] 51.7 (10.64) [52] 0.631 56.3 (9.08) [31]
SF-36 PCS [mean (S.D.)]a 34.8 (12.14) [242] 30.1 (11.89) [112] 0.001 36.2 (12.56) [90] 33.5 (11.86) [52] 0.22 41.6 (11.97) [31]
All variables shown as mean values, except medians for ESR and SvdH. SF-36 scores were only available from ERAN. T-test
for continuous variables, Chi-squared for categorical variables, MannWhitney U (non-parametric) for ESR and SvdH. aNumber
with available data given in square brackets. *mRDAS vs mLDAS. **sRDAS vs sLDAS. mRDAS: mean remission DAS; mLDAS:
mean low DAS; sLDAS: sustained low DAS; sRDAS: sustained remission DAS; sBR: sustained Boolean remission; IQR:
interquartile range; SvdH: Sharp van der Heijde; SF-36: Short Form 36 Health Survey Questionnaire; MCS: mental component
score; PCS: physical component score.
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Outcomes in mRDAS vs mLDAS groups, adjusted
model
The estimated mean scores in the adjusted mixed effects
models from baseline to year 5 for each of the functional,
QoL and radiographic outcomes (HAQ, SF-36 MCS, SF-
36 PCS and total SvdH scores), in patients categorized as
mRDAS, mLDAS and the entire ERAS/ERAN cohort, are
shown in Fig. 2. For all outcomes the differences in mean
scores between the mRDAS and mLDAS groups at each
year 15 time point were highly statistically different
(P-value 0.001 to <0.0001), and increasingly divergent
with each successive year in favour of mRDAS, see
Table 2. In relation to the minimally clinical important
difference for an individual, for each outcome the group
differences exceeded this threshold. When controlling
for additional baseline covariates (ESR, BMI, pain, comor-
bidities, social deprivation, DAS28 and smoking), the ef-
fects comparing mLDAS vs mRDAS remain significant
(data not shown). Repeating the analyses restricted to
patients with three or more DAS values available from
years 15 for allocation to either mRDAS or mLDAS
groups resulted in no difference in the pattern or statistical
significance of the outcomes.
Outcomes in sRDAS vs sLDAS groups and sBR vs
sLDAS adjusted models
The estimated mean scores in the adjusted mixed effects
models from baseline to year 5 for each of the functional,
QoL and radiographic outcomes (HAQ, SF-36 MCS, SF-
36 PCS and total SvdH scores), in patients categorized as
sRDAS, sLDAS and the entire ERAS/ERAN cohort, are
shown in Fig. 3, and in patients categorized as sBR,
sLDAS and the entire ERAS/ERAN cohort in supplemen-
tary Fig. S1, available at Rheumatology online.
Comparing the sRDAS vs sLDAS groups (Table 3),
mean HAQ, SF-36 MCS, SF-36 PCS and total SvdH
scores were increasingly divergent with each successive
year, favouring sRDAS over sLDAS, and were statistically
significant from year 1 onwards for HAQ, SF-36 MCS and
PCS (P-value 0.05 to <0.0001) and from year 3 for SvdH
(P = 0.05). In relation to the minimal clinically important
difference (MCID) for an individual, the mean differences
FIG. 2 HAQ, SF-36 MCS, SF-36 PCS and total SvdH estimated mean scores in entire ERAS/ERAN cohort and patients
categorized as mLDAS and mRDAS
Patients categorized as mean LDAS or mean RDAS based on mean score from years 1, 2 3, 4 and 5. Analysis controlled
for year of recruitment, age of RA onset, gender and baseline treatment. SF-36: Short Form 36 Health Survey
Questionnaire; MCS: mental component score; PCS: physical component score; SvdH: Sharp van der Heijde; ERAS/
ERAN: Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network; mLDAS: mean low DAS; mRDAS: mean
remission DAS.
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between the groups were in excess of the threshold for
SF-36 PCS scores from year 1, for SF-36 MCS from year 2
and for SvdH from year 3, but not greater than this thresh-
old for HAQ.
Comparing outcomes in the sBR vs sLDAS groups (sup-
plementary Table S4, available at Rheumatology online),
mean HAQ, SF-36 PCS and SF-36 MCS scores were all
highly statistically significantly better in the sBR group
FIG. 3 HAQ, SF-36 MCS, SF-36 PCS and total SvdH estimated mean scores in entire ERAS/ERAN cohort and patients
categorized as sLDAS and sRDAS
Patients categorized as sustained LDAS or sustained RDAS based on outcomes at both year 1 and 2. Analysis controlled
for year of recruitment, age of RA onset, gender and baseline treatment. SF-36: Short Form 36 Health Survey
Questionnaire; MCS: mental component score; PCS: physical component score; SvdH: Sharp van der Heijde;
ERAS/ERAN: Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network; sLDAS: sustained low DAS; sRDAS:
sustained remission DAS.
TABLE 2 Difference in estimated mean scores (95% CI) per year between mLDAS and mRDAS groups
MCID Baseline Year 1 Year 2 Year 3 Year 4 Year 5
HAQ 0.22 0.10
(0.030.18)
0.27
(0.20 0.34)
0.29
(0.23 0.35)
0.31
(0.24 0.37)
0.33
(0.26 0.40)
0.34
(0.27 0.42)
P = 0.007 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
SF-36 MCS 3.0 1.41
(0.68 to 3.51)
4.78
(6.85 2.71)
4.80
(6.62 2.98)
4.82
(6.65 2.99)
4.84
(6.93 2.75)
4.86
(7.39 2.34)
NS P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
SF-36 PCS 3.0 3.46
(5.76 1.16)
7.51
(9.78 5.24)
7.61
(9.61 5.61)
7.70
(9.71 5.70)
7.80
(10.09 5.51)
7.90
(10.66 5.13)
P = 0.003 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Total SvdH 5.0 2.41
(0.65 4.17)
5.20
(2.07 8.32)
6.44
(2.76 10.13)
8.15
(3.61 12.70)
10.05
(4.46 15.64)
12.77
(5.49 20.04)
P = 0.007 P = 0.001 P = 0.001 P < 0.0001 P < 0.0001 P = 0.001
mLDAS: mean low DAS; mRDAS: mean remission DAS; MCID: minimal clinically important difference; SF-36: Short Form 36
Health Survey Questionnaire; MCS: mental component score; PCS: physical component score; SvdH: Sharp van der Heijde.
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from year 1 onwards (P-value 0.002 - <0.0001), and in-
creasingly divergent for HAQ and SF-36 MCS with each
successive year. Total SvdH mean scores showed in-
creasingly divergent less radiographic progression in
sBR vs sLDAS at all time points, but this did not reach
statistical significance. In relation to the MCID for an indi-
vidual, the group differences exceeded this threshold for
HAQ, SF-36 MCS and SF-36 PCS at all time points, and
for total SvdH score at year 4 and 5. The differences in
HAQ, SF-36 MCS and SF-36 PCS mean scores between
the sBR and sLDAS groups were much greater than the
comparison between sRDAS and sLDAS (see Table 3 and
supplementary Table S4, available at Rheumatology
online). At year 5 the difference in mean scores, respect-
ively, were HAQ 0.35 and 0.18, SF-36 MCS 9.27 and 4.26,
and SF-36 PCS 8.48 and 5.62. Using the alternate
Boolean definition criterion of ESR <10 mmHg/h (rather
than 20 mmHg/h) for those cases where CRP was not
available, or ESR <20 mmHg/h for all cases, resulted in
no difference to the pattern or significance of results
across all outcomes.
Discussion
This study reports significant and increasingly divergent
differences in functional, QoL and radiographic outcomes
over 5 years, favouring patients in remission over low dis-
ease activity in the ERAS and ERAN inception cohorts.
These findings reflect outcomes from a conservative treat-
ment approach, in routine care, at a time when more ag-
gressive T2T strategies and bDMARDs were yet to be
widely introduced. Nonetheless, for those patients who
achieved remission (DAS28<2.6), whether defined by
mean scores from year 15 or by sustained scores at
years 1 and 2, outcomes were significantly better than
those achieving low disease activity (DAS28 2.63.2).
The magnitude of difference on a group level was in
excess of the MCID threshold used to assess individual
outcomes for each of HAQ, SF-36 MCS, PCS and SvdH
scores at every time point over 5 years comparing mRDAS
with mLDAS, and at many time points comparing sLDAS
with either sRDAS or sBR.
The DAS28 definition of remission is the least stringent
composite measure, in comparison with Boolean criteria
or the Simplified/Clinical Disease Activity Indices (SDAI,
CDAI). As such our finding of significant differences
across all outcomes between low disease activity and
the DAS28 definition of remission emphasizes the clinical
importance of these data. A more stringent criteria of re-
mission would predict even greater differences in out-
comes compared with low disease activity. Using the
Boolean criteria of remission, we found greater differ-
ences in HAQ and SF-36 MCS and PCS outcomes in
the sLDAS vs sBR models than in the sLDAS vs sRDAS
models. This was not the case for the total SvdH score.
This may reflect greater statistical uncertainty as there
were fewer individuals in the sBR than sRDAS categories.
However, it is noteworthy that whilst Boolean criteria are
strict on all components, with scores for patient global
assessment, swollen joint count, tender joint count and
CRP (mg/dl) all required to be <1, the equivalent quoted
ESR is up to 20 mm/h in men and 30 mm/h in women [21,
22]. The ESR is influenced by age, haemoglobin, RF and
total immunoglobulins, thus making it a less standardized
measure of the inflammatory response. We allowed an
ESR up to 20 mm/h for men and women to fulfil Boolean
remission for individuals where CRP was not available
(60% of all observations). We suspect this may be too
high and potentially a reason for greater radiographic pro-
gression in those allocated to the sBR group, and hence
an absence of significant difference in total SvdH scores
between the sBR and sLDAS groups. In keeping with this,
O’Dell and Mikuls found in the Veterans Affairs RA registry
that a lower ESR <10 mm/h was a reasonable surrogate
for a CRP <1 mg/dl [27]. Our data may therefore be a
conservative estimate of sBR associations with outcomes;
however, repeating the analysis with ESR <10 mm/h as
the criterion for inclusion in sBR continued to show non
significance in mean total SvdH scores between sBR and
sLDAS groups at all time points.
TABLE 3 Difference in estimated mean scores (95% CI) per year in sLDAS vs sRDAS groups
MCID Baseline Year 1 Year 2 Year 3 Year 4 Year 5
HAQ 0.22 0.07
(0.170.02)
0.15
(0.240.06)
0.16
(0.240.08)
0.17
(0.240.08)
0.17
(0.26 0.08)
0.18
(0.27 0.08)
NS P = 0.001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
SF-36
MCS
3.0 0.81
(2.203.83)
2.82
(0.005.64)
3.18
(0.665.70)
3.54
(0.996.09)
3.90
(1.02 6.79)
4.26
(0.81 7.72)
NS P = 0.05 P = 0.01 P = 0.006 P = 0.008 P = 0.015
SF-36
PCS
3.0 2.80
(0.606.21)
5.50
(2.328.67)
5.53
(2.718.35)
5.56
(2.708.41)
5.59
(2.33 8.85)
5.62
(1.69 9.54)
NS P = 0.01 P < 0.0001 P < 0.0001 P = 0.001 P = 0.005
Total
SvdH
5.0 1.47
(3.72 to 0.79)
3.14
(6.83 to 0.55)
4.14
(8.65 to 0.38)
5.49
(11.17 to 0.19)
7.02
(14.06 to 0.02)
9.23
(18.33 to 0.12)
NS NS NS P = 0.058 P = 0.051 P = 0.047
sLDAS: sustained low DAS; sRDAS: sustained remission DAS; SvdH: Sharp van der Heijde; SF-36: Short Form 36 Health
Survey Questionnaire; MCS: mental component score; PCS: physical component score; MCID: minimal clinically important
difference; NS: not significant.
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Our findings apply to early RA and are not necessarily
generalizable to patients with disease duration beyond
5 years. Indeed, EULAR guidelines state that an LDAS
target applies especially to patients who have failed pre-
vious therapies [2], and who are therefore likely to have
longer standing disease. This reflects the fact that some
items of the composite outcome scores that are used,
such as the patient global score and tender joint counts
in CDAI and DAS28, may lose plasticity in chronic disease,
given accrued joint damage, non-inflammatory pain and
changes in mental health. In such cases improving the
DAS into the remission range may be difficult to achieve,
or inappropriate to attempt by escalation of immune sup-
pression. We therefore emphasize that our findings only
support EULAR and ACR guidelines to aim for remission
in patients with early disease.
Our data are in keeping with findings from the Canadian
Early Arthritis Cohort (CATCH) at year 2, where HAQ and
visual analogue scale scores for pain and fatigue were
significantly better for those achieving sustained remis-
sion compared with sustained low disease activity (both
defined by CDAI or SDAI), with the magnitude also in
excess of MCID for HAQ on a group level [28].
Striving to achieve remission over low disease activity
has implications for clinical practice. In ERAS/ERAN there
was no protocolized treatment approach, with contem-
porary conservative use of csDMARDs in most patients,
and a relatively low proportion achieving DAS28 remission
as a consequence. Adopting a rigorous T2T strategy is
likely to lead to more patients achieving remission, not-
withstanding the resource implications of more clinical ap-
pointments, increased health-related administrative costs,
use of higher doses of therapies with associated monitor-
ing and toxicity costs, and more patients progressing to
high-cost targeted synthetic DMARDs or bDMARD.
Nonetheless, data indicate that when used as intended,
intensely and in combination, csDMARDs can be very ef-
fective in early RA [29], and T2T strategies cost effective in
early RA [30]. However, it is worth remembering that real-
world data indicate poor adherence of patients and phys-
icians to T2T strategies [7, 8].
The strength of this study is inherent in the nature of
ERAS and ERAN, two real-world large inception early RA
cohorts, recruiting all-comers, treated according to con-
temporary best practice, with the rigour of regular stan-
dardized assessments and data collection, allowing data
to be pooled and analysed collectively. In contrast to ran-
domized controlled trials, the data from ERAS and ERAN
are not restricted to defined RA populations with strict
inclusion and exclusion criteria, nor to treatment strate-
gies confined by protocol. ERAS and ERAN are also
unique in size, recruiting 2701 patients.
A limitation of this study is that patients did not achieve
consistently, over 5 years, the DAS outcome of the group
to which they were allocated. Although patients allocated
to the mRDAS group showed very high adherence to re-
mission DAS scores from year 15, the lower adherence in
patients allocated to mLDAS was inevitable given the
much narrower range of scores fulfilling this criterion
(2.63.2). Where scores in patients allocated to mLDAS
deviated, they did so as much into the RDAS as into
higher DAS categories (supplementary Table S2, available
at Rheumatology online). This reflects real-world vari-
ations in disease activity that are characteristic of RA.
That such significant and clinically meaningful differences
were seen in this situation we believe makes these find-
ings all the more powerful, given the increasing diver-
gence in functional, QoL and structural outcomes
favouring mRDAS over mLDAS from years 15. Other limi-
tations are the historical nature of the ERAS and ERAN
cohorts at a time when T2T strategies, first-line combin-
ation csDMARDs and early escalation to bDMARDs were
not widely used, and this is likely the reason why the over-
all proportion of patients achieving remission and low dis-
ease activity was low.
In conclusion, we have shown highly significant and clin-
ically meaningful associations between improved functional,
QoL and structural outcomes in early RA patients achieving
remission compared with low disease activity up to year 5 in
the ERAS/ERAN real-world inception cohorts. These find-
ings come from analyses using the least strict criterion of
remission in clinical practice, based on the DAS28 score,
either defined by mean values from year 15 or on sus-
tained values at year 1 and 2. Analyses using the stricter
Boolean remission criterion reveals more striking differ-
ences in function and QoL outcome measures compared
with patients achieving low disease activity. These findings
support ACR and EULAR guidelines that in early RA the
primary goal should be remission.
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